Portfolio company
Ouro Medicines
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Evommune
This biotechnology company develops medicinal therapies to treat patients suffering from chronic inflammatory and immune-mediated diseases.
SEITO Biologics AG
This biotechnology company develops selective regulatory T cell engagers to treat patients suffering from autoimmune diseases, chronic inflammation and organ transplant rejection.
Epana Bio
This company develops precision T-cell engagers and biologics using artificial intelligence and genomics to treat patients with autoimmune diseases.
HI-Bio
This biotechnology company develops targeted therapies for patients suffering from severe immune-mediated diseases.
Thymmune
This biotechnology company develops scalable thymic cell therapies to restore immune function for patients with immunodeficiencies, autoimmune disorders, and transplant-related conditions.
Beeline Medicines
This clinical-stage biotechnology company develops precision therapies for patients living with autoimmune and inflammatory diseases.
Egle Therapeutics
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.